Skip to main content
Premium Trial:

Request an Annual Quote

The Worst?

TheStreet's Adam Feuerstein wants to know who you think has been the worst biotech CEO of 2011. There have been several missteps in the world of biotech this year, Feuerstein says, like "a desperate, $11 billion Hail Mary acquisition, two botched drug launches, a clueless, tin-eared investor relations strategy, and an expensive and quixotic quest to develop a product no one needs."

Feuerstein has nominated five contenders for the "Worst Biotech CEO of 2011 Award," and is counting on readers to vote for who they think is the worst.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.